Zealand Pharma A/S reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was DKK 106.41 million compared to DKK 56.53 million a year ago. Net loss was DKK 198.89 million compared to DKK 228.57 million a year ago. Basic loss per share from continuing operations was DKK 4.61 compared to DKK 5.76 a year ago. For the nine months, sales was DKK 238.55 million compared to DKK 289.96 million a year ago. Net loss was DKK 737.89 million compared to DKK 466.18 million a year ago. Basic loss per share from continuing operations was DKK 17.26 compared to DKK 12.39 a year ago.